Literature DB >> 19769538

Development of reduced vancomycin susceptibility in methicillin-susceptible Staphylococcus aureus.

Satish K Pillai1, Christine Wennersten, Lata Venkataraman, George M Eliopoulos, Robert C Moellering, Adolf W Karchmer.   

Abstract

BACKGROUND: Most cases of reduced vancomycin susceptibility in Staphylococcus aureus reported in the literature have been in methicillin-resistant strains. We report the development of reduced vancomycin susceptibility in a series of clonally related, methicillin-susceptible S. aureus (MSSA) clinical isolates. This isogenic series permitted us to determine whether the evolution of reduced vancomycin susceptibility in MSSA is similar to that seen in MRSA.
METHODS: Differences in vancomycin population analysis profiles; chemical autolysis; vancomycin, oxacillin, and daptomycin minimum inhibitory concentrations; and bactericidal activities were examined.
RESULTS: Progressive vancomycin resistance correlated with increasing daptomycin nonsusceptibility. Chemical autolysis and the bactericidal activity of vancomycin, oxacillin, and daptomycin were reduced in the final, vancomycin-intermediate S. aureus isolate, compared with the vancomycin-susceptible MSSA progenitor.
CONCLUSIONS: Clinicians should recognize that reduced vancomycin susceptibility can occur in S. aureus irrespective of background methicillin susceptibility and that development of intermediate vancomycin susceptibility in MSSA may result in increased tolerance to several classes of anti-staphylococcal antibiotics.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19769538     DOI: 10.1086/605636

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  28 in total

1.  Development of daptomycin nonsusceptibility with heterogeneous vancomycin-intermediate resistance and oxacillin susceptibility in methicillin-resistant Staphylococcus aureus during high-dose daptomycin treatment.

Authors:  Chen-Hsiang Lee; Ming-Chung Wang; I-Wen Huang; Feng-Jui Chen; Tsai-Ling Lauderdale
Journal:  Antimicrob Agents Chemother       Date:  2010-06-28       Impact factor: 5.191

2.  Reduced Vancomycin Susceptibility of Methicillin-Susceptible Staphylococcus aureus Has No Significant Impact on Mortality but Results in an Increase in Complicated Infection.

Authors:  Sean B Sullivan; Eloise D Austin; Stephania Stump; Barun Mathema; Susan Whittier; Franklin D Lowy; Anne-Catrin Uhlemann
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

3.  Impact of an Antimicrobial Stewardship Intervention on Within- and Between-Patient Daptomycin Resistance Evolution in Vancomycin-Resistant Enterococcus faecium.

Authors:  Clare L Kinnear; Twisha S Patel; Carol L Young; Vincent Marshall; Duane W Newton; Andrew F Read; Robert J Woods
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

4.  Predicting methicillin resistance among community-onset Staphylococcus aureus bacteremia patients with prior healthcare-associated exposure.

Authors:  S-Y Chen; W-C Chiang; M H-M Ma; P-R Hsueh; S-C Chang; C-C Fang; S-C Chen; W-J Chen; W-C Chie; M-S Lai
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-05-19       Impact factor: 3.267

5.  In vitro activity of dalbavancin and five comparator agents against common and uncommon Gram-positive organisms isolated from cancer patients.

Authors:  Kenneth V I Rolston; Weiqun Wang; Lior Nesher; Samuel A Shelburne; Randall A Prince
Journal:  J Antibiot (Tokyo)       Date:  2015-12-02       Impact factor: 2.649

Review 6.  Mechanisms of vancomycin resistance in Staphylococcus aureus.

Authors:  Susana Gardete; Alexander Tomasz
Journal:  J Clin Invest       Date:  2014-07-01       Impact factor: 14.808

7.  Use of daptomycin in complicated cases of infective endocarditis.

Authors:  I Das; T Saluja; R Steeds
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-02-15       Impact factor: 3.267

8.  Serine/threonine phosphatase Stp1 contributes to reduced susceptibility to vancomycin and virulence in Staphylococcus aureus.

Authors:  David R Cameron; Doyle V Ward; Xenia Kostoulias; Benjamin P Howden; Robert C Moellering; George M Eliopoulos; Anton Y Peleg
Journal:  J Infect Dis       Date:  2012-04-05       Impact factor: 5.226

9.  Novel combinations of vancomycin plus ceftaroline or oxacillin against methicillin-resistant vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA.

Authors:  B J Werth; C Vidaillac; K P Murray; K L Newton; G Sakoulas; P Nonejuie; J Pogliano; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2013-02-19       Impact factor: 5.191

10.  Structures of two bacterial resistance factors mediating tRNA-dependent aminoacylation of phosphatidylglycerol with lysine or alanine.

Authors:  Stefanie Hebecker; Joern Krausze; Tatjana Hasenkampf; Julia Schneider; Maike Groenewold; Joachim Reichelt; Dieter Jahn; Dirk W Heinz; Jürgen Moser
Journal:  Proc Natl Acad Sci U S A       Date:  2015-08-10       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.